Enhanced intranasal insulin delivery by formulations and tumor protein-derived protein transduction domain as an absorption enhancer
Autor: | Jeehye Maeng, Seong Hoon Jeong, Kinam Park, Nam Ah Kim, Kyunglim Lee, Hae Duck Bae, Ritu Thapa |
---|---|
Rok vydání: | 2019 |
Předmět: |
Drug Compounding
medicine.medical_treatment Biological Availability Pharmaceutical Science Cell-Penetrating Peptides 02 engineering and technology Protein aggregation Pharmacology 03 medical and health sciences Pharmacokinetics Translationally-controlled tumor protein medicine Animals Insulin Rats Wistar Administration Intranasal 030304 developmental biology 0303 health sciences Chemistry 021001 nanoscience & nanotechnology Bioavailability Osmolyte Female Nasal administration Mannitol 0210 nano-technology medicine.drug |
Zdroj: | Journal of Controlled Release. 294:226-236 |
ISSN: | 0168-3659 |
DOI: | 10.1016/j.jconrel.2018.12.023 |
Popis: | One of the key factors for successful development of an intranasal insulin formulation is an absorption enhancer that would deliver insulin efficiently across nasal membranes without causing damage to mucosa or inducing protein aggregation under physiological conditions. In the present study, a protein transduction domain (PTD1) and its L-form with the double substitution A6L and I8A (PTD4), derived from human translationally controlled tumor protein, were used as absorption enhancers. PTD4 exhibited higher compatibility with insulin in terms of biophysical properties analyzed using μDSC, DLS, and CD. In addition, thermodynamic properties indicated stable complex formation but higher propensity of protein aggregation. Arginine hydrochloride (ArgHCl) was used to suppress protein aggregation and carbohydrates (i.e., mannitol, sucrose, and glycerin) were used as osmolytes in the formulation. The relative bioavailability of insulin co-administered intranasally using PTD4, 16 mg/mL glycerin and 100 mM ArgHCl was 58% and that using PTD4, 1 w/v% sucrose, and 25 mM ArgHCl was 53% of the bioavailability obtained via the subcutaneous route. These values represented a remarkable increase in bioavailability of intranasal insulin, causing a significant decrease in blood glucose levels within one hour. The pharmacokinetic properties of intranasal absorption were dependent on the concentration of carbohydrates used. These results suggest that the newly designed formulations with PTD represent a useful platform for intranasal delivery of insulin and other biomolecules. |
Databáze: | OpenAIRE |
Externí odkaz: |